Loading...
XOSL
AZT
Market cap82mUSD
Apr 30, Last price  
16.45NOK
1D
3.38%
1Q
18.48%
Jan 2017
48.67%
IPO
-26.87%
Name

Arcticzymes Technologies ASA

Chart & Performance

D1W1MN
P/E
110.95
P/S
8.05
EPS
0.15
Div Yield, %
—
Shrs. gr., 5y
2.01%
Rev. gr., 5y
6.20%
Revenues
104m
-12.26%
70,041,00072,973,00073,217,00051,702,00024,075,00025,909,00023,032,00021,475,00022,108,00033,026,00053,280,00071,904,00066,686,00066,769,00077,247,00093,449,000127,970,000136,971,000118,939,000104,352,000
Net income
8m
-61.02%
-15,446,000-26,654,000-18,665,000-52,179,000-99,372,000-28,541,000-20,103,000-24,318,000-22,889,000-21,992,000-17,344,000-20,480,000-24,938,000-13,989,000-7,183,00083,119,00046,380,00032,860,00019,425,0007,572,000
CFO
2m
-92.80%
-8,468,000-32,590,0000-65,657,000-89,000,000-24,965,000-10,811,000-24,583,000-17,385,000-21,200,000-12,886,000-19,278,000-22,056,000-18,279,0003,965,00046,928,00074,970,00058,094,00024,430,0001,759,000
Earnings
May 06, 2025

Profile

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining DNA /RNA fragments. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in Tromsø, Norway.
URL
https://arcticzymes.com/
IPO date
Nov 04, 2005
Employees
60
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
104,352
-12.26%
118,939
-13.16%
136,971
7.03%
Cost of revenue
5,983
28,504
30,053
Unusual Expense (Income)
NOPBT
98,369
90,435
106,918
NOPBT Margin
94.27%
76.03%
78.06%
Operating Taxes
3,119
5,340
9,283
Tax Rate
3.17%
5.90%
8.68%
NOPAT
95,250
85,095
97,635
Net income
7,572
-61.02%
19,425
-40.89%
32,860
-29.15%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,023
2,584
1,600
BB yield
-0.28%
-0.12%
-0.04%
Debt
Debt current
3,735
4,174
3,732
Long-term debt
12,463
21,002
24,428
Deferred revenue
Other long-term liabilities
(1,000)
1,000
2
Net debt
(227,737)
(153,439)
(213,870)
Cash flow
Cash from operating activities
1,759
24,430
58,094
CAPEX
(933)
(1,673)
(12,432)
Cash from investing activities
(9,864)
(21,015)
(12,432)
Cash from financing activities
(1,834)
(1,316)
(1,924)
FCF
88,194
75,785
103,132
Balance
Cash
243,935
249,862
242,030
Long term investments
(71,247)
Excess cash
238,717
172,668
235,181
Stockholders' equity
57,580
45,350
23,080
Invested Capital
273,868
276,536
275,738
ROIC
34.61%
30.82%
35.28%
ROCE
29.68%
28.10%
35.78%
EV
Common stock shares outstanding
53,383
50,841
50,928
Price
13.34
-68.24%
42.00
-41.38%
71.65
-23.78%
Market cap
712,134
-66.65%
2,135,322
-41.48%
3,648,991
-23.21%
EV
484,397
1,981,883
3,435,121
EBITDA
104,950
96,816
111,939
EV/EBITDA
4.62
20.47
30.69
Interest
498
499
Interest/NOPBT
0.55%
0.47%